Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
Abstract: Introduction Gastric cancer has become the third leading cause of cancer deaths globally. It accounts for 5.7% of cancer around the world, with a rate of mortality around 8.2%. Evaluation of human epidermal growth factor receptor 2 (HER2)/neu overexpression for targeted therapies is presently the mainstay of treatment in gastric cancer. High Ki-67 index expression in gastric cancer is an indicator of poor prognosis. Objectives To study the prevalence of HER2/neu expression and Ki-67 index in various types, sites, grade, and stage of gastric adenocarcinoma and to determine the correlation between HER2/neu expression and Ki-67 index. Materials and Methods This is a prospective study in a tertiary care hospital, Kolkata from January 2019 to June 2020. Gastrectomy and endoscopic biopsy of gastric adenocarcinoma were studied for histopathology and immunohistochemistry (HER2/neu and Ki-67 index). Statistical analysis used: SPSS (version 21.0, IBM, Chicago, Illinois, United States) for windows software. Results Among 54 cases, most of them were intestinal type, antral, moderately differentiated, stage III cases. HER2 expression and high Ki-67 index were observed in 28.0 and 40.75% cases, respectively. Statistically significant correlation was found in both HER2 expression and high Ki-67 index with location of the tumor and pathological nodal (pN) stage. A positive correlation was found between HER2/neu score and Ki-67 index (p = 0.007) (correlation coefficient = 0.4). Conclusion A positive correlation was found between HER2/neu positivity and high Ki-67 index, both were associated with higher pathological tumor stage and pN stage. So, advanced cases may be considered for targeted therapy using trastuzumab.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry ; volume:45 ; number:05 ; year:2024 ; pages:422-429
Indian journal of medical & paediatric oncology ; 45, Heft 05 (2024), 422-429
- Beteiligte Personen und Organisationen
-
Nisar, Saiqa
Naskar, Sukla
Biswas, Saumitra
- DOI
-
10.1055/s-0044-1788308
- URN
-
urn:nbn:de:101:1-2412121034203.247447361676
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nisar, Saiqa
- Naskar, Sukla
- Biswas, Saumitra
Ähnliche Objekte (12)
Is HER2 amplification predictable by digital immunohistochemistry?
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry
Imaging spectrum of lung adenocarcinoma with histopathological correlation
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma
New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China
Recurrence of pancreatic ductal adenocarcinoma after complete histopathological remission caused by FOLFIRINOX
Is HER2 amplification predictable by digital immunohistochemistry?
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry
Imaging spectrum of lung adenocarcinoma with histopathological correlation
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma
New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China
Recurrence of pancreatic ductal adenocarcinoma after complete histopathological remission caused by FOLFIRINOX
Is HER2 amplification predictable by digital immunohistochemistry?
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry
Imaging spectrum of lung adenocarcinoma with histopathological correlation
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma
New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China